resulted in a 15.5% weight reduction in obese rats.
Semaglutide treatment led to a 10.7% weight reduction in rats fed a high-fat diet.
treatment resulted in weight reductions of 5.0%, 14.9%, and 17.7% at concentrations of 10, 50, and 100 nmol/kg, respectively.
Metabolic analyte levels decreased in rats treated with semaglutide and tirzepatide compared to the sham group.
Adipose tissue weight and liver fat droplets were reduced in the intervention groups.
Tirzepatide, especially at higher doses, showed greater improvements in metabolic parameters compared to bariatric surgery and semaglutide.
Simplified
OBJECTIVES: is a well-established treatment for obesity and type 2 diabetes. , a dual GIP/GLP-1 receptor agonist, has emerged as a promising therapy for type 2 diabetes. This study aimed to compare the effects of bariatric surgery, semaglutide (a GLP-1 receptor agonist), and tirzepatide in Sprague-Dawley rats fed a high-fat diet.
METHODS: Rats were divided into surgery, semaglutide, and tirzepatide treatment groups, along with a control group (sham). Weight, oral glucose tolerance, and levels of metabolic markers were assessed, along with adipose and liver tissue analysis.
RESULTS: Surgery led to a 15.5% weight reduction, while rats treated with semaglutide exhibited a 10.7% reduction. Tirzepatide treatment at various concentrations (10, 50, and 100 nmol/kg) resulted in weight reductions of 5.0%, 14.9%, and 17.7%, respectively, compared to the sham group. Metabolic analyte levels decreased in intervention groups compared to the sham group, indicating improved metabolic health and glucose tolerance. Adipose tissue weight and hepatic liver fat droplets decreased in the intervention groups.
CONCLUSION: Bariatric surgery and tirzepatide treatment significantly improved metabolic parameters in obese rats. Tirzepatide, particularly at higher concentrations, showed pronounced improvements compared to surgery and semaglutide. These findings suggest that high doses of tirzepatide could be explored as an alternative to bariatric surgery for the treatment of obesity.
Key numbers
17.7%
Weight Reduction with
Weight loss in rats treated with at 100 nmol/kg.
15.5%
Weight Reduction with
Weight loss in rats following after 6 weeks.
10.7%
Weight Reduction with
Weight loss in rats treated with after 6 weeks.
Full Text
We can’t show the full text here under this license.
The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
